Feed JAZZ
JA

Jazz Pharmaceuticals plc JAZZ NASDAQ · Healthcare · Ireland

$230.26 -2.62% -$6.19

Market cap
$15.2B
Enterprise value
$18.8B
P/E
73.7x
Forward P/E
-
PEG
-
P/S
3.2x
P/FCF
9.7x
EV/EBITDA
16.1x
ROIC
7.2%
Gross margin
88.2%
Net margin
4.4%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
3.1x
Beta
0.32
Free float
97.0%

Sector

Healthcare

Industry

Biotechnology

CEO

Renee D. Gala

Employees

2,890

Headquarters

Dublin

Valuation

Is today's price reasonable?

  • What speaks for it: The share price is below the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Analysts expect revenue to grow by 13% this fiscal year.
  • What to watch: Revenue growth is slowing: 5.3% a year over the last 3 years against 13% over 5 years.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: Out of every 100 USD of revenue, 33 USD is left as free cash.

Financial health

Can it carry its debt?

  • What to watch: Operating profit covers the interest on its debt only 2.4 times.

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy